title: Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease.
abstract: Recent studies demonstrated that glycoprotein (GP) IIb/IIIa receptor antagonists improve endothelial dysfunction of forearm resistance vessels in patients with stable coronary artery disease. However, it remains unclear whether these findings can be extended to the conductance vessel level. In this study, we aimed to evaluate the acute effect of tirofiban on endothelial function of arterial conductance vessels in patients undergoing percutaneous coronary intervention (PCI). Endothelial function was examined by ultrasonographic measurement of flow-mediated vasodilation (FMD) of the brachial artery. Endothelium-independent vasodilation was determined in response to nitroglycerin. Sixty-six patients who underwent PCI were included in the study. Thirty-three patients received a bolus of 10 microg/kg body weight of tirofiban, whereas 33 patients who did not receive tirofiban served as the control group. FMD was measured in all patients before and 30 minutes after PCI. Tirofiban significantly improved FMD (6.0 +/- 0.4% before vs 7.8 +/- 0.5% after PCI, p <0.0001), whereas FMD deteriorated in patients in the control group (6.1 +/- 0.6% before vs 4.7 +/- 0.7% after PCI, p = 0.006). Nitroglycerin-induced dilation remained unaltered in response to PCI. In another group of 11 patients with coronary artery disease, FMD did not change after coronary angiography without coronary intervention. In conclusion, PCI induces endothelial dysfunction in forearm conductance vessels that can be reversed with tirofiban.
authors.affiliation: Division of Cardiology, The University Hospital Eppendorf, Hamburg, Germany. warnholtz@2-med.klinik.uni-mainz.de <warnholtz@2-med.klinik.uni-mainz.de>
authors.forename: Ascan
authors.initials: A
authors.lastname: Warnholtz
authors.forename: Mir Abolfazl
authors.initials: MA
authors.lastname: Ostad
authors.forename: Thomas
authors.initials: T
authors.lastname: Heitzer
authors.forename: Britta U
authors.initials: BU
authors.lastname: Goldmann
authors.forename: Goetz
authors.initials: G
authors.lastname: Nowak
authors.forename: Thomas
authors.initials: T
authors.lastname: Munzel
mesh_terms: D000368:Aged; D001916:Brachial Artery; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000503:physiopathology* / Q000628:therapy; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000494:pharmacology* / Q000627:therapeutic use*; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban